Work

CML-1107: Asciminib Demonstrates Comparable Tolerability and Efficacy With Once-Daily (QD) and Twice-Daily (BID) Dosing in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Analysis (Week 72) of the Phase 3b AIM4CML Trial

Year: 2025

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01985-8

Authors: Moshe Levy, David Andorsky, Ghayas Issa, James Essell, Camille Abboud, Andrea Damon, Amy Starinsky, David Coleman, Dheeraj Gianchandani, Michael Mauro, Michael Deininger

Institutions: Baylor Scott & White Health, Rocky Mountain Cancer Centers, The University of Texas MD Anderson Cancer Center, Oncology Hematology Care, Washington University in St. Louis, Novartis (Switzerland), Novartis (India), Memorial Sloan Kettering Cancer Center, University of Utah

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413813930

Cites:

Cited by:

Related to: 10